PTSD Psychopharmacology Working Group calls attention to the crisis in PTSD pharmacotherapy and identifies NMDA receptor antagonism as the most promising target for future treatments.

A consensus statement of the PTSD Psychopharmacology Working Group has clearly identified treatment of PTSD, a disease without any effective pharmacotherapy, as a severe unmet medical need. The group has analyzed scientific data on potential efficacy of a multitude of receptor targets and identified NMDA receptor antagonism as the most promising approach to future treatments.